Inhibition of Marburg Virus RNA Synthesis by a Synthetic Anti-VP35 Antibody

Parmeshwar Amatya, Nicole Wagner, Gang Chen, Priya Luthra, Liuqing Shi, Dominika Borek, Alevtina Pavlenco, Henry Rohrs, Christopher F. Basler, Sachdev S. Sidhu, Michael L. Gross, Daisy W. Leung

Research output: Contribution to journalArticle

Abstract

Marburg virus causes sporadic outbreaks of severe hemorrhagic fever with high case fatality rates. Approved, effective, and safe therapeutic or prophylactic countermeasures are lacking. To address this, we used phage display to engineer a synthetic antibody, sFab H3, which binds the Marburg virus VP35 protein (mVP35). mVP35 is a critical cofactor of the viral replication complex and a viral immune antagonist. sFab H3 displayed high specificity for mVP35 and not for the closely related Ebola virus VP35. sFab H3 inhibited viral-RNA synthesis in a minigenome assay, suggesting its potential use as an antiviral. We characterized sFab H3 by a combination of biophysical and biochemical methods, and a crystal structure of the complex solved to 1.7 Å resolution defined the molecular interface between the sFab H3 and mVP35 interferon inhibitory domain. Our study identifies mVP35 as a therapeutic target using an approach that provides a framework for generating engineered Fabs targeting other viral proteins.

Original languageEnglish (US)
JournalACS Infectious Diseases
DOIs
StatePublished - Jan 1 2019

Fingerprint

Marburgvirus
Anti-Idiotypic Antibodies
RNA
Viral RNA
Viral Proteins
Bacteriophages
Interferons
Antiviral Agents
Disease Outbreaks
Fever
Mortality
Antibodies
Therapeutics
Proteins

Keywords

  • IFN antagonist
  • Marburg virus
  • mass spectrometry
  • phage display
  • synthetic antibodies
  • VP35
  • X-ray crystallography

ASJC Scopus subject areas

  • Infectious Diseases

Cite this

Inhibition of Marburg Virus RNA Synthesis by a Synthetic Anti-VP35 Antibody. / Amatya, Parmeshwar; Wagner, Nicole; Chen, Gang; Luthra, Priya; Shi, Liuqing; Borek, Dominika; Pavlenco, Alevtina; Rohrs, Henry; Basler, Christopher F.; Sidhu, Sachdev S.; Gross, Michael L.; Leung, Daisy W.

In: ACS Infectious Diseases, 01.01.2019.

Research output: Contribution to journalArticle

Amatya, P, Wagner, N, Chen, G, Luthra, P, Shi, L, Borek, D, Pavlenco, A, Rohrs, H, Basler, CF, Sidhu, SS, Gross, ML & Leung, DW 2019, 'Inhibition of Marburg Virus RNA Synthesis by a Synthetic Anti-VP35 Antibody', ACS Infectious Diseases. https://doi.org/10.1021/acsinfecdis.9b00091
Amatya, Parmeshwar ; Wagner, Nicole ; Chen, Gang ; Luthra, Priya ; Shi, Liuqing ; Borek, Dominika ; Pavlenco, Alevtina ; Rohrs, Henry ; Basler, Christopher F. ; Sidhu, Sachdev S. ; Gross, Michael L. ; Leung, Daisy W. / Inhibition of Marburg Virus RNA Synthesis by a Synthetic Anti-VP35 Antibody. In: ACS Infectious Diseases. 2019.
@article{fb1660b07f7e431e9ef2e30aac13bc61,
title = "Inhibition of Marburg Virus RNA Synthesis by a Synthetic Anti-VP35 Antibody",
abstract = "Marburg virus causes sporadic outbreaks of severe hemorrhagic fever with high case fatality rates. Approved, effective, and safe therapeutic or prophylactic countermeasures are lacking. To address this, we used phage display to engineer a synthetic antibody, sFab H3, which binds the Marburg virus VP35 protein (mVP35). mVP35 is a critical cofactor of the viral replication complex and a viral immune antagonist. sFab H3 displayed high specificity for mVP35 and not for the closely related Ebola virus VP35. sFab H3 inhibited viral-RNA synthesis in a minigenome assay, suggesting its potential use as an antiviral. We characterized sFab H3 by a combination of biophysical and biochemical methods, and a crystal structure of the complex solved to 1.7 {\AA} resolution defined the molecular interface between the sFab H3 and mVP35 interferon inhibitory domain. Our study identifies mVP35 as a therapeutic target using an approach that provides a framework for generating engineered Fabs targeting other viral proteins.",
keywords = "IFN antagonist, Marburg virus, mass spectrometry, phage display, synthetic antibodies, VP35, X-ray crystallography",
author = "Parmeshwar Amatya and Nicole Wagner and Gang Chen and Priya Luthra and Liuqing Shi and Dominika Borek and Alevtina Pavlenco and Henry Rohrs and Basler, {Christopher F.} and Sidhu, {Sachdev S.} and Gross, {Michael L.} and Leung, {Daisy W.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1021/acsinfecdis.9b00091",
language = "English (US)",
journal = "ACS Infectious Diseases",
issn = "2373-8227",
publisher = "American Chemical Society",

}

TY - JOUR

T1 - Inhibition of Marburg Virus RNA Synthesis by a Synthetic Anti-VP35 Antibody

AU - Amatya, Parmeshwar

AU - Wagner, Nicole

AU - Chen, Gang

AU - Luthra, Priya

AU - Shi, Liuqing

AU - Borek, Dominika

AU - Pavlenco, Alevtina

AU - Rohrs, Henry

AU - Basler, Christopher F.

AU - Sidhu, Sachdev S.

AU - Gross, Michael L.

AU - Leung, Daisy W.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Marburg virus causes sporadic outbreaks of severe hemorrhagic fever with high case fatality rates. Approved, effective, and safe therapeutic or prophylactic countermeasures are lacking. To address this, we used phage display to engineer a synthetic antibody, sFab H3, which binds the Marburg virus VP35 protein (mVP35). mVP35 is a critical cofactor of the viral replication complex and a viral immune antagonist. sFab H3 displayed high specificity for mVP35 and not for the closely related Ebola virus VP35. sFab H3 inhibited viral-RNA synthesis in a minigenome assay, suggesting its potential use as an antiviral. We characterized sFab H3 by a combination of biophysical and biochemical methods, and a crystal structure of the complex solved to 1.7 Å resolution defined the molecular interface between the sFab H3 and mVP35 interferon inhibitory domain. Our study identifies mVP35 as a therapeutic target using an approach that provides a framework for generating engineered Fabs targeting other viral proteins.

AB - Marburg virus causes sporadic outbreaks of severe hemorrhagic fever with high case fatality rates. Approved, effective, and safe therapeutic or prophylactic countermeasures are lacking. To address this, we used phage display to engineer a synthetic antibody, sFab H3, which binds the Marburg virus VP35 protein (mVP35). mVP35 is a critical cofactor of the viral replication complex and a viral immune antagonist. sFab H3 displayed high specificity for mVP35 and not for the closely related Ebola virus VP35. sFab H3 inhibited viral-RNA synthesis in a minigenome assay, suggesting its potential use as an antiviral. We characterized sFab H3 by a combination of biophysical and biochemical methods, and a crystal structure of the complex solved to 1.7 Å resolution defined the molecular interface between the sFab H3 and mVP35 interferon inhibitory domain. Our study identifies mVP35 as a therapeutic target using an approach that provides a framework for generating engineered Fabs targeting other viral proteins.

KW - IFN antagonist

KW - Marburg virus

KW - mass spectrometry

KW - phage display

KW - synthetic antibodies

KW - VP35

KW - X-ray crystallography

UR - http://www.scopus.com/inward/record.url?scp=85067081571&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067081571&partnerID=8YFLogxK

U2 - 10.1021/acsinfecdis.9b00091

DO - 10.1021/acsinfecdis.9b00091

M3 - Article

C2 - 31120240

AN - SCOPUS:85067081571

JO - ACS Infectious Diseases

JF - ACS Infectious Diseases

SN - 2373-8227

ER -